Inclusion Criteria:

1. Willing and able to read, understand, and sign the informed consent.

2. Female at birth, 18-65 years of age at the time of study entry.

3. Must have smartphone with internet access to complete surveys online.

4. Diagnosis of Long COVID according to any of the following definitions Infected
individuals will have a history of suspected, probable, or confirmed SARS-CoV-2
infection as defined by WHO criteria and at least three months of persistent fatigue
and muscle weakness, functional impairment, and cognitive impairment since the acute
infection.

Adults with suspected SARS-CoV-2 infection. An adult qualifies as having suspected
SARS-CoV-2 infection if meeting at least one of the following criteria (a-e) below:

a. Clinical criteria: Acute onset of fever and cough OR acute onset of any three or more of
the following signs or symptoms: fever, cough, general weakness /fatigue, headache,
myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered mental
status. These patients should also meet one of the following epidemiological criteria: i.
Epidemiological criteria:

1. Residing or working in an area with a high risk of transmission of virus: closed
residential settings, humanitarian settings such as camp and camp-like settings for
displaced persons; anytime within the 14 days before symptom onset; or

2. Residing or travel to an area with community transmission anytime within the 14 days
before symptom onset; or

3. Working in any health care setting, including within health facilities or the
community, anytime within the 14 days before symptom onset.

b. A patient with severe acute respiratory illness: (acute respiratory infection with
history of fever or measured fever of ≥38C°; and cough; with onset within the last ten
days; and requires hospitalization).

c. An asymptomatic patient not meeting any of the epidemiologic criteria above but
with a previously positive SARS-CoV-2 Antigen- RDT.

d. Adults with probable SARS-CoV-2 infection. An adult qualifies as having probable
SARS-CoV-2 infection if meeting any one of 1-3 below: i. A patient who meets clinical
criteria for suspected SARS- CoV-2 AND is a contact of a probable or confirmed case or
linked to a COVID-19 cluster; ii. A suspect case with chest imaging showing findings
suggestive of COVID-19 disease; iii. A person with recent onset of anosmia (loss of
smell) or ageusia (loss of taste) in the absence of any other identified cause; e.
Adults with confirmed SARS-CoV-2 infection. An adult qualifies as having confirmed
SARS-CoV-2 infection if meeting any one of 1-4 below: i. Any person with a positive
Nucleic Acid Amplification Test (NAAT); ii. Any person with of a positive SARS-CoV-2
Antigen-RDT AND meeting either the probable case definition or suspect criteria A OR
B; iii. An asymptomatic person with a positive SARS-CoV-2 Antigen-RDT who is a contact
of a probable or confirmed case; iv. Any person with a positive SARS-CoV-2
nucleocapsid protein antibody test OR a positive SARS-CoV-2 spike protein antibody
test IF not vaccinated

5. Women of child-bearing potential must have a negative serum pregnancy test at screening
and agree to on-site urine pregnancy testing at all subsequent study visits. Women
confirmed to be of non-childbearing potential do not require pregnancy testing. Pregnancy
tests will not be required for remote visits. To be considered of non-child-bearing
potential, the patient must be:

a. Post-menopausal (defined as no menses for at least one year); or b. Surgically sterile
(s/p hysterectomy, bilateral oophorectomy, or bilateral tubal ligation at least six months
prior to beginning treatment with study drug); or c. At least three months s/p a
non-surgical permanent sterilization procedure 6. A urine drug screen performed at the
Screening Visit must be negative for drugs of abuse such as methamphetamine, cocaine,
phencyclidine (PCP), and non-disclosed amphetamines and opioids/opiates. The following
stipulations also apply:

1. Patients with a positive screening UDS due to prescribed amphetamines for allowed
conditions do not require further UDS testing. They may proceed with study treatment,
assuming no evidence of abuse or dependency.

2. Patients positive for prescribed opioids at the Screening Visit yet deemed appropriate
for washout and study participants must have a negative repeat UDS at the Baseline
Visit.

7. Patients must be willing and able to withdraw and refrain from chronic use of
antivirals (as defined in Exclusion Criterion, below). In the judgement of the
investigator, it must be medically advisable for these therapies to be withdrawn.

8. Qualified patients with mild to moderate depression who in the judgment of the
investigator are not at risk of suicidal ideation or behavior. The dose of allowed
antidepressants should have been stable for at least 30 days prior to Baseline Visit..

9. In the opinion of the Investigator, the patient is willing and able to comply with
all protocol-specified requirements.

10. Women of child-bearing potential must be willing to utilize an effective birth
control method for the duration of the study. Allowable contraceptive methods include:

a. Oral, implantable, injectable, or transdermal hormonal contraceptives (should have been
used for a minimum of one full cycle prior to administration of study drug) b. Intrauterine
devices (IUD) c. Double barrier method (male or female condom, sponge, diaphragm, or
vaginal ring with simultaneous use of spermicidal jelly or cream) 11. Patients should not
require routine treatment with warfarin, heparin, lithium, digoxin, amiodarone, isoniazid,
phenytoin, fluconazole, methotrexate, probenecid, or raloxifene. Patients on these
medications should not be screened. PRN usage of fluconazole for short time periods is
permitted.

12. Patients must have successfully completed at least two PROMIS Fatigue and two PROMIS
Sleep Disturbance surveys a minimum of 7 days apart during the interval leading up to the
baseline visit.

Exclusion Criteria:

1. Breastfeeding, pregnant, or planning to become pregnant during the next six months.

2. In the opinion of the Investigator, any clinically significant, uncontrolled, or
unstable medical or surgical condition that could affect the patient's ability to
participate in the study or potentially compromise her well-being while enrolled in
the study.

3. In the opinion of the Investigator or based on results of the HADS, evidence of a
clinically significant psychiatric disorder; e.g., severe, unstable or poorly
controlled depression, anxiety or obsessive-compulsive disorder; moderate or severe
alcohol use disorder; substance use disorder other than mild cannabis use disorder; or
any history of bipolar disorder, schizophrenia, schizoaffective disorder or other
psychotic disorder.

4. A score of >15 on the Patient Health Questionnaire-9 (PHQ-9) determined by survey at
screening.

5. A positive response to thoughts of suicide or self-harm on the PHQ-9 determined by
survey at screening.

6. A diagnosis of ME/CFS prior to January 2020.

7. Any anticipated need for surgery that in the opinion of the Principal Investigator or
Sub-I might confound results or interfere with the patient's ability to comply with
the protocol.

8. Symptomatic and/or otherwise clinically significant cardiac disease, including but not
limited to myocardial infarction during the preceding two years; uncontrolled
hypertension; symptomatic heart failure (e.g., New York Heart Association Class II or
higher); angina or other evidence of significant coronary artery disease; clinically
significant cardiac rhythm or conduction abnormality or anticipation of bypass or
other cardiac surgery within the next 12 months.

9. Acute non-COVID systemic infection (e.g., HIV, hepatitis) or other active viral or
bacterial infection during the screening/washout period or at the Baseline visit.
(Patient may remain in screening until the active infection has resolved, or re-screen
after recuperation.)

10. Currently receiving chronic systemic corticosteroids (>5 mg prednisone daily, or
equivalent).

11. Uncontrolled sleep apnea. Patients successfully treated with CPAP or other devices are
eligible.

12. Use of chronic nucleoside analog antiviral suppression therapy within one month of the
Screening Visit or requiring on average more than one acute treatment course every two
months.

13. Current use of celecoxib either alone or in combination with valacyclovir or
famciclovir

14. In the opinion of the Investigator, evidence of current drug or alcohol abuse or
dependency, or history of abuse or dependence during the preceding 12 months.

15. The patient has undergone a malabsorptive weight loss procedure (e.g., Roux-en-Y or
other bypass procedure).

16. Severe IBS-C or colonic inertia as evidenced by seven or more days between bowel
movements.

17. History of significant adverse reaction or allergy to sulfonamides, celecoxib,
famciclovir, acyclovir, valacyclovir or penciclovir cream (Denavir®).

18. History of aspirin-sensitive asthma, or any other history of other allergic- type
reactions after taking aspirin or other NSAID such as asthma or urticaria.

19. History of Sulfa Allergy.

20. History of peptic ulcer disease or upper gastrointestinal bleeding that is thought to
pose a significant risk of GI bleeding with the daily use of celecoxib.

21. Clinically significant elevations of AST, ALT, or bilirubin at the screening
assessment (or at the last assessment prior to baseline, if repeated) in the opinion
of the Investigator.

22. Presence of active kidney disease, as evidenced by an estimated glomerular filtration
rate (eGFR) of less than 60 mL/min/1.73m2.

23. History of acute kidney injury within the past year, any history of chronic kidney
disease stage 3 or higher.

24. In the opinion of the Investigator, evidence of other clinically significant
laboratory abnormality(ies) based on the screening laboratory assessments and/or
medical history.

25. Untreated, symptomatic gall bladder disease (i.e., symptoms within preceding six
months).

26. Plans to undergo vaccination against Herpes varicella/ zoster (i.e., shingles or
chickenpox) during the study. Instead, vaccination should be completed at least 14
days prior to the Baseline Visit or delayed until at least two weeks after the last
dose of study medication.

27. Patients known or suspected to be slow CYP2C9 metabolizers based on genotype or
previous history/experience with other CYP2C9 substrates (such as warfarin, phenytoin,
glimepiride, tolbutamide, celecoxib, meloxicam, piroxicam, or ibuprofen).

28. Investigational drug usage within 30 days of Screening.